CymaBay Therapeutics (NASDAQ:CBAY) will present two abstracts related to its seladelpar program for treating primary biliary cholangitis at The Liver Meeting in November.
Seladelpar is a “potent and selective peroxisome
proliferator-activated receptor delta agonist” that’s in a global phase 3
registration study for treating PBC, as well as phase 2 studies for
treating nonalcoholic steatohepatitis and primary sclerosing
cholangitis.
In a dataset covering PBC patients with cirrhosis,
seladelpar exposures were comparable to non-cirrhotic PBC patients over
12 weeks.
The Liver Meeting takes place in Boston from Nov. 8-12.
https://seekingalpha.com/news/3503128-cymabay-presenting-two-abstracts-liver-meeting
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.